Predictive and Prognostic Value of Non-coding RNA in Breast Cancer

Sobhani, Navid; Chahwan, Richard; Roudi, Raheleh; Morris, Rachel; Volinia, Stefano; Chai, Dafei; D’Angelo, Alberto; Generali, Daniele

doi:10.20944/preprints202205.0342.v1

Cited by 3 publications

(1 citation statement)

References 152 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Non-coding RNAs (ncRNAs), which comprise 99% of the total cellular RNAs in human cells (Consortium, 2012;Romano et al, 2017), have recently attracted much attention in relation to BC pathogenesis and development (Sobhani et al, 2022). In brief, ncRNAs are a large family of RNA molecules, classified into two subclasses based on their size: minor or short ncRNAs with less than 200 nucleotides in size (Krichevsky et al, 2003) and major or long ncRNAs with more than 200 nucleotides in size.…”

Section: Introductionmentioning

confidence: 99%

The landscape of exosomal non-coding RNAs in breast cancer drug resistance, focusing on underlying molecular mechanisms

et al. 2023

View full text Add to dashboard Cite

Breast cancer (BC) is the most common malignancy among women worldwide. Like many other cancers, BC therapy is challenging and sometimes frustrating. In spite of the various therapeutic modalities applied to treat the cancer, drug resistance, also known as, chemoresistance, is very common in almost all BCs. Undesirably, a breast tumor might be resistant to different curative approaches (e.g., chemo- and immunotherapy) at the same period of time. Exosomes, as double membrane-bound extracellular vesicles 1) secreted from different cell species, can considerably transfer cell products and components through the bloodstream. In this context, non-coding RNAs (ncRNAs), including miRNAs, long ncRNAs (lncRNAs), and circular RNAs (circRNAs), are a chief group of exosomal constituents with amazing abilities to regulate the underlying pathogenic mechanisms of BC, such as cell proliferation, angiogenesis, invasion, metastasis, migration, and particularly drug resistance. Thereby, exosomal ncRNAs can be considered potential mediators of BC progression and drug resistance. Moreover, as the corresponding exosomal ncRNAs circulate in the bloodstream and are found in different body fluids, they can serve as foremost prognostic/diagnostic biomarkers. The current study aims to comprehensively review the most recent findings on BC-related molecular mechanisms and signaling pathways affected by exosomal miRNAs, lncRNAs, and circRNAs, with a focus on drug resistance. Also, the potential of the same exosomal ncRNAs in the diagnosis and prognosis of BC will be discussed in detail.

show abstract

Section: Introductionmentioning

confidence: 99%

The landscape of exosomal non-coding RNAs in breast cancer drug resistance, focusing on underlying molecular mechanisms

et al. 2023

View full text Add to dashboard Cite

show abstract

The Role of Genomics and Proteomics in Lung Cancer Early Detection and Treatment

Abbasian

Ardekani

Sobhani

et al. 2022

Cancers

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer-related death worldwide, with non-small-cell lung cancer (NSCLC) being the primary type. Unfortunately, it is often diagnosed at advanced stages, when therapy leaves patients with a dismal prognosis. Despite the advances in genomics and proteomics in the past decade, leading to progress in developing tools for early diagnosis, targeted therapies have shown promising results; however, the 5-year survival of NSCLC patients is only about 15%. Low-dose computed tomography or chest X-ray are the main types of screening tools. Lung cancer patients without specific, actionable mutations are currently treated with conventional therapies, such as platinum-based chemotherapy; however, resistances and relapses often occur in these patients. More noninvasive, inexpensive, and safer diagnostic methods based on novel biomarkers for NSCLC are of paramount importance. In the current review, we summarize genomic and proteomic biomarkers utilized for the early detection and treatment of NSCLC. We further discuss future opportunities to improve biomarkers for early detection and the effective treatment of NSCLC.

show abstract

Potential Impact of Preoperative Circulating Biomarkers on Individual Escalating/de-Escalating Strategies in Early Breast Cancer

Gianni

Palleschi

Merloni

et al. 2022

Cancers

View full text Add to dashboard Cite

The research on non-invasive circulating biomarkers to guide clinical decision is in wide expansion, including the earliest disease settings. Several new intensification/de-intensification strategies are approaching clinical practice, personalizing the treatment for each patient. Moreover, liquid biopsy is revealing its potential with multiple techniques and studies available on circulating biomarkers in the preoperative phase. Inflammatory circulating cells, circulating tumor cells (CTCs), cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), and other biological biomarkers are improving the armamentarium for treatment selection. Defining the escalation and de-escalation of treatments is a mainstay of personalized medicine in early breast cancer. In this review, we delineate the studies investigating the possible application of these non-invasive tools to give a more enlightened approach to escalating/de-escalating strategies in early breast cancer.

show abstract

Predictive and Prognostic Value of Non-coding RNA in Breast Cancer

Cited by 3 publications

References 152 publications

The landscape of exosomal non-coding RNAs in breast cancer drug resistance, focusing on underlying molecular mechanisms

The landscape of exosomal non-coding RNAs in breast cancer drug resistance, focusing on underlying molecular mechanisms

The Role of Genomics and Proteomics in Lung Cancer Early Detection and Treatment

Potential Impact of Preoperative Circulating Biomarkers on Individual Escalating/de-Escalating Strategies in Early Breast Cancer

Contact Info

Product

Resources

About